Drug Profile
SB 221420A
Alternative Names: SB 221420Latest Information Update: 16 Mar 2000
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Neuroprotectants
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 16 Mar 2000 New profile
- 16 Mar 2000 Discontinued-Preclinical for Neurological disorders (Prevention) in United Kingdom (Unknown route)